NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - General · USD

Organon & Co. (OGN) Stock Analysis

Organon & Co. (OGN) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

OGN

$13.75

−$0.01 (−0.07%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OGN with… →

OGN Key Statistics

As of Oct 21, 2026
Trading
Open
$13.75
Previous Close
$13.76
Day's Range
13.74–13.77
52-Week Range
5.69–13.83
Volume
2.56M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.54
Valuation
Market Cap
$3.61B
P/E Ratio
17.63
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
3.80
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.59
EPS (ttm)Profit attributable to each share over the last twelve months.
0.78
Financials (FY)
Revenue (FY)
$6.22B−2.92%
Net Income (FY)
$187.00M−78.36%
Profit marginThe share of revenue left as profit after all costs and taxes.
3.41%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
262.61M
1-Year Return
+53.46%
Dividend and dates
Dividend
$0.08+0.58%
Ex-Dividend Date
August 14, 2026
Earnings Date
November 9, 2026estimated
Avg Volume
2.70M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OGN closed at $13.75, +53.46% over 1 year.

Organon & Co. (OGN) has a market capitalization of $3.61B.

In fiscal 2025, OGN reported revenue of $6.22B.

OGN Stock Return by Calendar Year

Organon & Co. (OGN) return since May 2021: what $10,000 became

1 year
$10,000 $15,346
+53.46%
5 years
$10,000 $4,732
−52.68%
Since May 2021
$10,000 $5,074
−49.26%

If you had invested $10,000 in Organon & Co. (OGN) at the close on May 14, 2021, the earliest close on record here, it would have been worth $5,074 at the close on October 21, 2026: −49.26% in total, −11.73% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+92.53%
2025−50.71%
2024+9.92%
2023−45.12%
2022−4.86%
2021 (partial year)−6.84%

As of October 21, 2026.

OGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.22B$187.00M3.0%
2024$6.40B$864.00M13.5%
2023$6.26B$1.02B16.3%
2022$6.17B$917.00M14.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.22B$3.31B$1.23B$187.00M3.0%
2024$6.40B$3.72B$1.49B$864.00M13.5%
2023$6.26B$3.75B$1.33B$1.02B16.3%
2022$6.17B$3.88B$1.71B$917.00M14.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OGN Dividend History

$0.34−69.6% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.063—
2025$0.344−69.6%
2024$1.124+0.0%
2023$1.124+0.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.063—
2025$0.344−69.6%
2024$1.124+0.0%
2023$1.124+0.0%
2022$1.124+100.0%
2021$0.562—

Most recent payment: $0.02 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

OGN Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricOGNDrug Manufacturers - General medianvs median
P/E17.6325.2330% below
P/S ratio0.593.230.2x the median
Profit margin3.41%9.80%6.4 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Organon & Co. (OGN) at $3.61B. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. Headcount on file is 10,000.

The most recent close on file for OGN is $13.75, dated October 21, 2026. That is −$0.01 (−0.07%) against the previous close. The 52-week range on file runs from $5.69 to $13.83. The latest close sits 141.65% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $6.22B. Against the prior fiscal year total of $6.40B, that is a change of −2.92%. The same year closed with net income of $187.00M. That is −78.36% against the prior fiscal year. Profit margin runs at 3.41%. That is 6.4 percentage points below the Drug Manufacturers - General median of 9.8%. Earnings per share on a trailing basis come to 0.78.

Across the 4 fiscal years on file, revenue moves from $6.17B in 2022 to $6.22B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 17.63. That is 30.12% below the Drug Manufacturers - General median of 25.23. The forward P/E on file is 3.8. The price-to-sales ratio is 0.59. On price-to-sales that is 0.2 times the Drug Manufacturers - General median of 3.23. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +53.46%. Measured over 5 years, that is −13.90% a year compounded. The reported beta is 1.54. Daily returns over the trailing 5 years annualize to a volatility of 47.31%.

Growth & Income

Shareholders receive a dividend, yielding 0.58% on the latest price. That is 1.7 percentage points below the Drug Manufacturers - General median yield of 2.3%. At the indicated rate that is $0.08 a share a year. The ex-dividend date on file is August 14, 2026. Dividends are recorded for 6 calendar years; 2026 shows 3 payments totalling $0.06 a share. The year before, 2025, totalled $0.34 a share.

Across the complete calendar years on file, 2024 returned +9.92% and 2025 returned −50.71%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is +92.53% year to date.

Peer Comparison

Organon & Co. (OGN) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Organon & Co. OGN $3.61B 17.6
Eli Lilly and Company LLY $1.13T 42.7
Johnson & Johnson JNJ $621.22B 39.1
AbbVie Inc. ABBV $503.27B 80.5

The Drug Manufacturers - General industry average P/E ratio is 25.2x. Organon & Co. trades at a P/E of 17.6.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 MRK

Merck & Co., Inc.

$369.78B

 NVS

Novartis AG

$292.58B

 AZN

AstraZeneca PLC

$261.82B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$374.30B

 TMO

Thermo Fisher Scientific Inc.

$256.61B

 AMGN

Amgen Inc.

$236.98B

 GILD

Gilead Sciences, Inc.

$190.42B

 ABT

Abbott Laboratories

$173.92B
View all Healthcare stocks →

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Visit website →